Top

Published in:

01-09-2012 | Review

Newborn screening and renal disease: where we have been; where we are now; where we are going

Authors: J. Lawrence Merritt II, David Askenazi, Si Houn Hahn

Published in: Pediatric Nephrology | Issue 9/2012

Abstract

Newborn screening (NBS) has rapidly changed since its origins in the 1960s. Beginning with a single condition, then a handful in the 1990s, NBS has expanded in the past decade to allow the detection of many disorders of amino-acid, organic-acid, and fatty-acid metabolism. These conditions often present with recurrent acute attacks of metabolic acidosis, hypoglycemia, liver failure, and hyperammonemia that may be prevented with initiation of early treatment. Renal disease is an important component of these disorders and is a frequent source of morbidity. Hemodialysis is often required for hyperammonemia in the organic acidemias and urea-cycle disorders. Rhabdomyolysis with renal failure is a frequent complication in fatty-acid oxidation disorders. Newer screening methods are under investigation to detect lysosomal storage diseases, primary immunodeficiencies, and primary renal disorders. These advances will present many challenges to nephrologists and pediatricians with respect to closely monitoring and caring for children with such disorders.

Guthrie R, Susi A (1963) A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338–343PubMed

Marsden D, Larson C, Levy HL (2006) Newborn screening for metabolic disorders. J Pediatr 148:577–584PubMedCrossRef

Carroll AE, Downs SM (2006) Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 117:S287–S295PubMed

Millington DS, Kodo N, Norwood DL, Roe CR (1990) Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 13:321–324PubMedCrossRef

Rinaldo P, Lim JS, Tortorelli S, Gavrilov D, Matern D (2008) Newborn screening of metabolic disorders: recent progress and future developments. Nestle Nutr Workshop Ser Pediatr Progr 62:81–93, discussion 93–86CrossRef

Group ACoMGNSE (2006) Newborn screening: toward a uniform screening panel and system–executive summary. Pediatrics 117:S296–S307

Group ACoMGNSE (2006) Newborn screening: toward a uniform screening panel and system. Genet Med 8(Suppl 1):1S–252S

Botkin JR, Clayton EW, Fost NC, Burke W, Murray TH, Baily MA, Wilfond B, Berg A, Ross LF (2006) Newborn screening technology: proceed with caution. Pediatrics 117:1793–1799PubMedCrossRef

Howell RR (2006) The high price of false positives. Mol Genet Metab 87:180–183PubMedCrossRef

10.

Natowicz M (2005) Newborn screening–setting evidence-based policy for protection. N Engl J Med 353:867–870PubMedCrossRef

11.

Baily MA, Murray TH (2008) Ethics, evidence, and cost in newborn screening. Hastings Cent Rep 38:23–31PubMedCrossRef

12.

Howell RR (2009) Every child is priceless: debating effective newborn screening policy. Hastings Cent Rep 39:4–6, author reply 7–8PubMedCrossRef

13.

Dionisi-Vici C, Deodato F, Roschinger W, Rhead W, Wilcken B (2006) 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis 29:383–389PubMedCrossRef

14.

Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, Strauss AW, Comeau AM, Eaton RB, Grady GF (2001) Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 47:1945–1955PubMed

15.

Tarini BA (2007) The current revolution in newborn screening: new technology, old controversies. Arch Pediatr Adolesc Med 161:767–772PubMedCrossRef

16.

Gregersen N, Andresen BS, Pedersen CB, Olsen RK, Corydon TJ, Bross P (2008) Mitochondrial fatty acid oxidation defects–remaining challenges. J Inherit Metab Dis 31:643–657PubMedCrossRef

17.

Oglesbee D, Sanders KA, Lacey JM, Magera MJ, Casetta B, Strauss KA, Tortorelli S, Rinaldo P, Matern D (2008) Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem 54:542–549PubMedCrossRef

18.

Arnold GL, Koeberl DD, Matern D, Barshop B, Braverman N, Burton B, Cederbaum S, Fiegenbaum A, Garganta C, Gibson J, Goodman SI, Harding C, Kahler S, Kronn D, Longo N (2008) A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 93:363–370PubMedCrossRef

19.

van Calcar SC, Gleason LA, Lindh H, Hoffman G, Rhead W, Vockley G, Wolff JA, Durkin MS (2007) 2-methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. WMJ 106:12–15PubMed

20.

Collins SA, Sinclair G, McIntosh S, Bamforth F, Thompson R, Sobol I, Osborne G, Corriveau A, Santos M, Hanley B, Greenberg CR, Vallance H, Arbour L (2010) Carnitine palmitoyltransferase 1A (CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nunavut. Mol Genet Metab 101:200–204PubMedCrossRef

21.

Bodamer OA, Hoffmann GF, Lindner M (2007) Expanded newborn screening in Europe 2007. J Inherit Metab Dis 30:439–444PubMedCrossRef

22.

Leonard JV, Dezateux C (2009) Newborn screening for medium chain acyl CoA dehydrogenase deficiency. Arch Dis Child 94:235–238PubMedCrossRef

23.

Lindner M, Ho S, Kolker S, Abdoh G, Hoffmann GF, Burgard P (2008) Newborn screening for methylmalonic acidurias–optimization by statistical parameter combination. J Inherit Metab Dis 31:379–385PubMedCrossRef

24.

Kumar J, Gordillo R, Kaskel FJ, Druschel CM, Woroniecki RP (2009) Increased prevalence of renal and urinary tract anomalies in children with congenital hypothyroidism. J Pediatr 154:263–266PubMedCrossRef

25.

Ataga KI, Orringer EP (2000) Renal abnormalities in sickle cell disease. Am J Hematol 63:205–211PubMedCrossRef

26.

Becker AM (2011) Sickle cell nephropathy: challenging the conventional wisdom. Pediatr Nephrol. doi:10.1007/s00467-010-1736-2

27.

Walter JH, Roberts RE, Besley GT, Wraith JE, Cleary MA, Holton JB, MacFaul R (1999) Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child 80:374–376PubMedCrossRef

28.

Berry GT, Segal S, Gitzelmann R (2006) Disorders of Galactose Metabolism. In: Fernandes J, Saudubray J-M, van den Berghe G, Walter JH (eds) Inborn Metabolic Diseases. Springer, Heidelberg, pp 121–130CrossRef

29.

Andrieux A, Harambat J, Bui S, Nacka F, Iron A, Llanas B, Fayon M (2010) Renal impairment in children with cystic fibrosis. J Cyst Fibros 9:263–268PubMedCrossRef

30.

Feillet F, Steinmann G, Vianey-Saban C, de Chillou C, Sadoul N, Lefebvre E, Vidailhet M, Bollaert PE (2003) Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med 29:1594–1597PubMedCrossRef

31.

Illsinger S, Lucke T, Peter M, Ruiter JP, Wanders RJ, Deschauer M, Handig I, Wuyts W, Das AM (2008) Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. Am J Med Genet A 146A:2925–2928PubMedCrossRef

32.

Meir K, Fellig Y, Meiner V, Korman SH, Shaag A, Nadjari M, Soffer D, Ariel I (2009) Severe infantile carnitine palmitoyltransferase II deficiency in 19-week fetal sibs. Pediatr Dev Pathol 12:481–486PubMedCrossRef

33.

Morris AA, Olpin SE, Van't Hoff WG, Johnson AW, Leonard JV (1997) Renal tubular dysfunction in multiple acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 20:604–605PubMedCrossRef

34.

Olpin SE, Allen J, Bonham JR, Clark S, Clayton PT, Calvin J, Downing M, Ives K, Jones S, Manning NJ, Pollitt RJ, Standing SJ, Tanner MS (2001) Features of carnitine palmitoyltransferase type I deficiency. J Inherit Metab Dis 24:35–42PubMedCrossRef

35.

Elpeleg ON, Hammerman C, Saada A, Shaag A, Golzand E, Hochner-Celnikier D, Berger I, Nadjari M (2001) Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet 102:183–187PubMedCrossRef

36.

Choi JH, Yoon HR, Kim GH, Park SJ, Shin YL, Yoo HW (2007) Identification of novel mutations of the HADHA and HADHB genes in patients with mitochondrial trifunctional protein deficiency. Int J Mol Med 19:81–87PubMed

37.

Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B (2009) Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol Genet Metab 98:195–197PubMedCrossRef

38.

Molteni KH, Oberley TD, Wolff JA, Friedman AL (1991) Progressive renal insufficiency in methylmalonic acidemia. Pediatr Nephrol 5:323–326PubMedCrossRef

39.

Ha TS, Lee JS, Hong EJ (2008) Delay of renal progression in methylmalonic acidemia using angiotensin II inhibition: a case report. J Nephrol 21:793–796PubMed

40.

Nagarajan S, Enns GM, Millan MT, Winter S, Sarwal MM (2005) Management of methylmalonic acidaemia by combined liver-kidney transplantation. J Inherit Metab Dis 28:517–524PubMedCrossRef

41.

Kind T, Levy J, Lee M, Kaicker S, Nicholson JF, Kane SA (2002) Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period. J Pediatr Hematol Oncol 24:327–329PubMedCrossRef

42.

McBryde KD, Kershaw DB, Bunchman TE, Maxvold NJ, Mottes TA, Kudelka TL, Brophy PD (2006) Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism. J Pediatr 148:770–778PubMedCrossRef

43.

Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, Sabetta G, Rizzoni G, Bartuli A (2001) Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol 16:862–867PubMedCrossRef

44.

Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E (1999) Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant 14:910–918PubMedCrossRef

45.

Puck JM (2007) Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol 120:760–768PubMedCrossRef

46.

Hubbard WC, Moser AB, Liu AC, Jones RO, Steinberg SJ, Lorey F, Panny SR, Vogt RF Jr, Macaya D, Turgeon CT, Tortorelli S, Raymond GV (2009) Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 97:212–220PubMedCrossRef

47.

Li Y, Brockmann K, Turecek F, Scott CR, Gelb MH (2004) Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 50:638–640PubMedCrossRef

48.

Marsden D, Levy H (2010) Newborn screening of lysosomal storage disorders. Clin Chem 56:1071–1079PubMedCrossRef

49.

Dajnoki A, Fekete G, Keutzer J, Orsini JJ, De Jesus VR, Chien YH, Hwu WL, Lukacs Z, Muhl A, Zhang XK, Bodamer O (2010) Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clin Chim Acta 411:1428–1431PubMedCrossRef

50.

Dajnoki A, Muhl A, Fekete G, Keutzer J, Orsini J, Dejesus V, Zhang XK, Bodamer OA (2008) Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem 54:1624–1629PubMedCrossRef

51.

Duffner PK, Caggana M, Orsini JJ, Wenger DA, Patterson MC, Crosley CJ, Kurtzberg J, Arnold GL, Escolar ML, Adams DJ, Andriola MR, Aron AM, Ciafaloni E, Djukic A, Erbe RW, Galvin-Parton P, Helton LE, Kolodny EH, Kosofsky BE, Kronn DF, Kwon JM, Levy PA, Miller-Horn J, Naidich TP, Pellegrino JE, Provenzale JM, Rothman SJ, Wasserstein MP (2009) Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 40:245–252, discussion 253–245PubMedCrossRef

52.

Duffey TA, Bellamy G, Elliott S, Fox AC, Glass M, Turecek F, Gelb MH, Scott CR (2010) A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler). Clin Chem 56:1854–1861PubMedCrossRef

53.

deWilde A, Sadilkova K, Sadilek M, Vasta V, Hahn SH (2008) Tryptic peptide analysis of ceruloplasmin in dried blood spots using liquid chromatography-tandem mass spectrometry: application to newborn screening. Clin Chem 54:1961–1968PubMedCrossRef

54.

Amstutz U, Andrey-Zurcher G, Suciu D, Jaggi R, Haberle J, Largiader CR (2011) Sequence capture and next-generation resequencing of multiple tagged nucleic acid samples for mutation screening of urea cycle disorders. Clin Chem 57:102–111PubMedCrossRef

55.

Fokstuen S, Munoz A, Melacini P, Iliceto S, Perrot A, Ozcelik C, Jeanrenaud X, Rieubland C, Farr M, Faber L, Sigwart U, Mach F, Lerch R, Antonarakis SE, Blouin JL (2011) Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. J Med Genet 48:572–576PubMedCrossRef

56.

Vasta V, Ng SB, Turner EH, Shendure J, Hahn SH (2009) Next generation sequence analysis for mitochondrial disorders. Genome Med 1:100PubMedCrossRef

57.

Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, Lymp J, Hahn SH, Rinaldo P, Matern D (2004) Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 50:621–625PubMedCrossRef

58.

Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P (2007) Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004–2007). J Inherit Metab Dis 30:585–592PubMedCrossRef

59.

Arnold GL, Van Hove J, Freedenberg D, Strauss A, Longo N, Burton B, Garganta C, Ficicioglu C, Cederbaum S, Harding C, Boles RG, Matern D, Chakraborty P, Feigenbaum A (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90PubMedCrossRef

60.

Vockley J, Ensenauer R (2006) Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet 142C:95–103PubMedCrossRef

61.

Grosse SD (2005) Does newborn screening save money? The difference between cost-effective and cost-saving interventions. J Pediatr 146:168–170PubMedCrossRef

62.

Prosser LA, Kong CY, Rusinak D, Waisbren SL (2010) Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 125:e286–e294PubMedCrossRef

63.

Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, Marsden D, Msall M, Naylor EW, Pueschel S, Seashore M, Shih VE, Levy HL (2003) Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290:2564–2572PubMedCrossRef

64.

Lipstein EA, Perrin JM, Waisbren SE, Prosser LA (2009) Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med 11:716–721PubMedCrossRef

65.

Zarate YA, Hopkin RJ (2008) Fabry's disease. Lancet 372:1427–1435PubMedCrossRef

66.

Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G (2009) Kidney transplantation in patients with Fabry disease. Transpl Int 22:475–481PubMedCrossRef

67.

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374:1986–1996PubMedCrossRef

68.

Wang RY, Bodamer OA, Watson MS, Wilcox WR (2011) Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 13:457–484PubMedCrossRef

69.

Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40PubMedCrossRef

70.

Beucher J, Leray E, Deneuville E, Roblin M, Pin I, Bremont F, Turck D, Ginies JL, Foucaud P, Rault G, Derelle J, David V, Journel H, Marchand S, Veillard D, Roussey M (2010) Psychological effects of false-positive results in cystic fibrosis newborn screening: a two-year follow-up. J Pediatr 156:771–776, 776 e771PubMedCrossRef

71.

Gennaccaro M, Waisbren SE, Marsden D (2005) The knowledge gap in expanded newborn screening: survey results from paediatricians in Massachusetts. J Inherit Metab Dis 28:819–824PubMedCrossRef

72.

Mc Guire PJ, Lim-Melia E, Diaz GA, Raymond K, Larkin A, Wasserstein MP, Sansaricq C (2008) Combined liver-kidney transplant for the management of methylmalonic aciduria: a case report and review of the literature. Mol Genet Metab 93:22–29PubMedCrossRef

73.

Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, Paradis K, Russo P (1999) The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 29:104–108PubMedCrossRef

74.

Santra S, Preece MA, Hulton SA, McKiernan PJ (2008) Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis 31:399–402PubMedCrossRef

75.

Bohm N, Uy J, Kiessling M, Lehnert W (1982) Multiple acyl-CoA dehydrogenation deficiency (glutaric aciduria type II), congenital polycystic kidneys, and symmetric warty dysplasia of the cerebral cortex in two newborn brothers. II. Morphology and pathogenesis. Eur J Pediatr 139:60–65PubMedCrossRef

76.

Distelmaier F, Vogel M, Spiekerkotter U, Gempel K, Klee D, Braunstein S, Groneck HP, Mayatepek E, Wendel U, Schwahn B (2007) Cystic renal dysplasia as a leading sign of inherited metabolic disease. Pediatr Nephrol 22:2119–2124PubMedCrossRef

77.

Harkin JC, Gill WL, Shapira E (1986) Glutaric acidemia type II. Phenotypic findings and ultrastructural studies of brain and kidney. Arch Pathol Lab Med 110:399–401PubMed

78.

Falik-Borenstein ZC, Jordan SC, Saudubray JM, Brivet M, Demaugre F, Edmond J, Cederbaum SD (1992) Brief report: renal tubular acidosis in carnitine palmitoyltransferase type 1 deficiency. N Engl J Med 327:24–27PubMedCrossRef

79.

Schadewaldt P, Killius S, Kamalanathan L, Hammen HW, Strassburger K, Wendel U (2003) Renal excretion of galactose and galactitol in patients with classical galactosaemia, obligate heterozygous parents and healthy subjects. J Inherit Metab Dis 26:459–479PubMedCrossRef

80.

Sechi LA, Colussi G, Di Fabio A, Catena C (2010) Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 23:1253–1260PubMedCrossRef

81.

del-Rio Camacho G, Tapia Ceballos L, Picazo Angelin B, Ruiz Moreno JA, Hortas Nieto ML, Romero Gonzalez J (2003) Renal failure and acquired hypothyroidism. Pediatr Nephrol 18:290–292PubMed

82.

Meeus L, Gilbert B, Rydlewski C, Parma J, Roussie AL, Abramowicz M, Vilain C, Christophe D, Costagliola S, Vassart G (2004) Characterization of a novel loss of function mutation of PAX8 in a familial case of congenital hypothyroidism with in-place, normal-sized thyroid. J Clin Endocrinol Metab 89:4285–4291PubMedCrossRef

83.

Mooraki A, Broumand B, Neekdoost F, Amirmokri P, Bastani B (2003) Reversible acute renal failure associated with hypothyroidism: report of four cases with a brief review of literature. Nephrology (Carlton) 8:57–60CrossRef

84.

Jouret F, Devuyst O (2009) CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch 457:1227–1236PubMedCrossRef

85.

Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 33:2677–2683PubMedCrossRef

86.

Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B (2010) Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 33:2697–2708PubMedCrossRef

87.

Soulsby N, Greville H, Coulthard K, Doecke C (2009) Renal dysfunction in cystic fibrosis: is there cause for concern? Pediatr Pulmonol 44:947–953PubMedCrossRef

88.

Becton LJ, Kalpatthi RV, Rackoff E, Disco D, Orak JK, Jackson SM, Shatat IF (2010) Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 25:1505–1511PubMedCrossRef

Title: Newborn screening and renal disease: where we have been; where we are now; where we are going
Authors: J. Lawrence Merritt II
David Askenazi
Si Houn Hahn
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 9/2012
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-011-1995-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Newborn screening and renal disease: where we have been; where we are now; where we are going

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2012

Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome

The role of genetics in drug dosing

When and how to start prevention of atherosclerosis? Lessons from the Cardiovascular Risk in the Young Finns Study and the Special Turku Coronary Risk Factor Intervention Project

Nutrition in infants and very young children with chronic kidney disease

GLCCI1 single nucleotide polymorphisms in pediatric nephrotic syndrome

Intima media thickness in children undergoing dialysis